Close Menu

Insurance companies and drugmakers are wrestling with the high cost of making and administering biologic drugs, says Avery Johnson on the Wall Street Journal's Health blog. These drugs can cost as much as $1.5 million a year, and patients and prescription plan payers are having a hard time affording them. On the other hand, Johnson adds, some of these drugs have "dramatic" results, sending sometimes-fatal diseases into remission.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.